Method for preparing Gynostemma pentaphyllum extract with increasing damulin A and damulin B contents, and pharmaceutical compositions of the same for treating metabolic disease
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07G-003/00
C07H-017/00
A01N-045/00
출원번호
US-0696362
(2010-01-29)
등록번호
US-8357786
(2013-01-22)
우선권정보
KR-10-2009-0065461 (2009-07-17)
발명자
/ 주소
Huh, Tae Lin
Song, He Bok
Kim, Ji Eun
Joon, So Young
Oh, Won Keun
출원인 / 주소
TG Biotech Co., Ltd.
인용정보
피인용 횟수 :
1인용 특허 :
0
초록▼
Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, a
Disclosed is an AMPK activating material used for improving and treating metabolic syndrome, in which AMPK (AMP-activated protein kinase) is a main enzyme for regulating an energy sensor and lipid/glucose metabolism in the body. The activation of AMPK inhibits the synthesis of fat and cholesterol, and accelerates the reduction of body fat and blood glucose, thereby improving obesity, diabetes, and hyperlipidaemia. The disclosed AMPK activating material contains, as active ingredients having an improving and treating effect on metabolic syndrome, including obesity, diabetes, and hyperlipidaemia, a novel compound 2α,3β,12β-trihydroxydammar-20(22)-E,24-diene-3-O-β-D-glucopyranosyl-(1→)-β-D-glucopyranoside, named Damulin A, and a novel compound 2α,3β,12β-trihydroxydammara-20,24-diene-3-O-β-D-glucopyranosyl-(1→)-β-D-glucopyranoside, named Damulin B. Herein, the contents of damulin A and damulin B (as active indicator ingredients for AMPK activation) can be increased by treating a Gynostemma pentaphyllum extract with high temperature/high pressure. Accordingly, the novel Gynostemma pentaphyllum extract with a significantly increased AMPK activating capability can be used for improving or treating metabolic syndrome, such as obesity, diabetes, and hyperlipidaemia.
대표청구항▼
1. A method for preparing a novel Gynostemma pentaphyllum extract having increased concentrations of damulin A and damulin B, comprising the step of: subjecting an ethanol extract of Gynostemma pentaphyllum leaves to a temperature of about 40-125° C. and a pressure of about 1.2˜1100 atmospheres for
1. A method for preparing a novel Gynostemma pentaphyllum extract having increased concentrations of damulin A and damulin B, comprising the step of: subjecting an ethanol extract of Gynostemma pentaphyllum leaves to a temperature of about 40-125° C. and a pressure of about 1.2˜1100 atmospheres for 1-24 hours to obtain increased concentrations of damulin A and damulin B, which are 0.7-7% (w/w) and 0.5-6% (w/w), respectively, based on the total weight of a dry powder of the novel Gynostemma pentaphyllum extract. 2. The novel Gynostemma pentaphyllum extract for improving and treating a metabolic syndrome, which is prepared by the method of claim 1. 3. The novel Gynostemma pentaphyllum extract as claimed in claim 2, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 4. A functional food for improving a metabolic syndrome comprising the Gynostemma pentaphyllum extract as claimed in claim 2, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 5. The functional food as claimed in claim 4, which comprises a carrier of thermal waters, filtrated water, distilled water, aerated water, juice, yogurt, milk, or edible oil. 6. A pharmaceutical composition for improving and treating a metabolic syndrome comprising the Gynostemma pentaphyllum extract as claimed in claim 2, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 7. The pharmaceutical composition as claimed in claim 6, which increases enzyme activity of AMP-activated protein kinase (AMPK). 8. A pharmaceutical composition for improving and treating a metabolic syndrome, comprising at least one of at least 0.7% damulin A and at least 0.5% damulin B, represented by Formula 1: and a pharmacologically acceptable carrier or excipient, wherein the metabolic syndrome is obesity, diabetes, or hyperlipidaemia. 9. The pharmaceutical composition as claimed in claim 8, which increases enzyme activity of AMP-activated protein kinase (AMPK). 10. A novel Gynostemma pentaphyllum extract comprising 0.7-7% (w/w) of damulin A and 0.5-6% (w/w) of damulin B based on the total weight of a dry powder of the Gynostemma pentaphyllum extract. 11. A method for improving or treating a metabolic syndrome comprising administering the novel Gynostemma pentaphyllum extract of claim 2 to a patient in need thereof in an effective amount for improving or treating the metabolic syndrome, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 12. A method for improving or treating a metabolic syndrome comprising administering the pharmaceutical composition of claim 8 to a patient in need thereof in an effective amount for improving or treating the metabolic syndrome, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 13. A method for improving or treating a metabolic syndrome comprising administering the novel Gynostemma pentaphyllum extract of claim 10 to a patient in need thereof in an effective amount for improving or treating the metabolic syndrome, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 14. Separated and purified damulin A represented by the following formula: 15. Separated and purified damulin B represented by the following formula: 16. A method for improving or treating a metabolic syndrome comprising administering the separated and purified damulin A of claim 14 to a patient in need thereof in an effective amount for improving or treating the metabolic syndrome, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia. 17. A method for improving or treating a metabolic syndrome comprising administering the separated and purified damulin B of claim 15 to a patient in need thereof in an effective amount for improving or treating the metabolic syndrome, wherein the metabolic syndrome is obesity, diabetes or hyperlipidaemia.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허를 인용한 특허 (1)
Durkee, Shane E.; Wilson, Gabriel, Nutritional supplement for the enhancement of muscle irisin and enhancement of brown fat, metabolic rate, and weight loss, and methods of use thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.